Asthma & COPD

SMi present their 8th annual Asthma & COPD event to be held in London on Monday 16th & Tuesday 17th of Apil 2012.  Building on the success of our previous Asthma & COPD, and COPD: Novel Therapeutics and Management Strategies events, this year will see an elite panel of speakers drawn for both industry and academia. The successful combination of academic KOLs and leading senior big Pharma speakers offers an ideal and comprehensive platform for the study of both Asthma & COPD. The similarities between the two conditions are juxtoposed with the the subtle and important differences. Both pose unique and complex challenges, and these differences must be identified and isolated. As respiratory research continues to grow and prosper this event contributes further towards the understanding of how they can be dealt with in a successful and cost effective manner. This event offers an ideal platform for those who have recently moved in to respiratory studies as well as established professionals. This is an opportunity to network with the leading protagonists in the field and to learn from their knowledge and experience as well as to share your own.

"The total financial burden of lung disease in Europe amounts to nearly €102 billion, a figure comparable to the annual gross domestic product (GDP) of the Republic of Ireland.
COPD contributes to almost one-half of this figure, followed by asthma, pneumonia, lung cancer and TB"

Source: http://www.european-lung-foundation.org/16-european-lung-foundation-elf-lung-diseases.htm

Why should you attend this event?

Study comparisons of exacerbations of Asthma & COPD Analyse the EXACT-PRO initiative and take lessons from it Investigate POET-COPD studies. What has been learned and what can be taken forward. Explore novel bronchodilators and how they should be used Understand combination therapies; clinical and exercise therapies. How can these be used more and more effectively. Isolate unmet needs in Asthma & COPD and debate how these needs can be met and addressed. Expand your knowledge of biomarkers in Asthma & COPD - discovery and validation. Develop and analyse ideas for new end points required for regulatory outcomes

Key Speakers  include:

• Professor Sebastian Johnston, Professor of Adult Respiratory Medicine, Imperial College School of Medicine
  
• Professor Peter Barnes, Head of Respiratory Medicine, Imperial College School of Medicine
  
• Thys van der Molen, Professor of Primary Care Respiratory Medicine, University of Groningen University Medical Centre Groningen Centre for Medical Biomics
  
• Professor Maria Belvisi, Head, Respiratory Pharmacology Group Pharmacology and Toxicology Section, National Heart & Lung Institute
  
• Stefano Petruzzelli, Head, Respiratory Medicine Unit Corporate Clinical Development, Chiesi Farmaceutici
  
• Louise Donnelly, Reader in Respiratory Cell Biology, National Heart & Lung Institute
  
• Professor Wisia Wedzicha, Professor Respiratory Medicine, University College London
  

Who should attend?

Industry professionals in positions such as:

Associate Clinician Associate Director Biomarker Specialist Brand Manager Business Development Director CEO Chief Executive Officer Chief Medical Officer Chief Scientific Officer Clinical & Regulatory Strategy Manager Clinical Pharmacologist Clinical Trial Manager Commercial Director CSO Director Director of Medical Affairs

Head Global Licensing Respiratory Head of Clinical Science Head of Discovery Head of Global Data Informatics - Global Preclinical R&D Head of In-Vitro Biology Head of Pharmacology Head of Respiratory Pharmacology Managing Director Medical Affairs Director Medical Director Principal Scientist Vice President VP Chemistry VP Inflammatory Disease Area VP, Clinical Research Immunology VP, Research

Attendees at previous SMi Asthma & COPD events include: 3M Healthcare, 4SC, Accovion, Actelion, Actimis, Activaero, Aeropharm, AstraZeneca, Bayer, Bedfont Scientific, Biomedical Systems Europe, Biotie Therapies, Boehringer Ingelheim, CareFusion, Centocor, Chiesi, Deepbreeze, Galapagos, Genentech, GSK, Grunenthal, Laboratorios Almirall, MedImmune, Merck, Mpex, Munidpharma, Napp, Novartis, Nycomed, Pfizer,Revotar, Roche, Sanofi-Aventis, Schering Plough, Sepracor, Synairgen, Topigen, UCB, Vitalograph